1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Oropharyngeal Candidiasis - Pipeline Review, H1 2015

Oropharyngeal Candidiasis - Pipeline Review, H1 2015

  • February 2015
  • -
  • Global Markets Direct
  • -
  • 37 pages

Oropharyngeal Candidiasis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Oropharyngeal Candidiasis - Pipeline Review, H1 2015’, provides an overview of the Oropharyngeal Candidiasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Oropharyngeal Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oropharyngeal Candidiasis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Oropharyngeal Candidiasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Oropharyngeal Candidiasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Oropharyngeal Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Oropharyngeal Candidiasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Oropharyngeal Candidiasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Oropharyngeal Candidiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Oropharyngeal Candidiasis - Pipeline Review, H1 2015
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Oropharyngeal Candidiasis Overview 6
Therapeutics Development 7
Pipeline Products for Oropharyngeal Candidiasis - Overview 7
Pipeline Products for Oropharyngeal Candidiasis - Comparative Analysis 8
Oropharyngeal Candidiasis - Therapeutics under Development by Companies 9
Oropharyngeal Candidiasis - Therapeutics under Investigation by Universities/Institutes 10
Oropharyngeal Candidiasis - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Oropharyngeal Candidiasis - Products under Development by Companies 14
Oropharyngeal Candidiasis - Products under Investigation by Universities/Institutes 15
Oropharyngeal Candidiasis - Companies Involved in Therapeutics Development 16
Eisai Co., Ltd. 16
Onxeo SA 17
Oropharyngeal Candidiasis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
E-1210 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
E-1211 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
miconazole - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Prof-002 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Oropharyngeal Candidiasis - Recent Pipeline Updates 30
Oropharyngeal Candidiasis - Discontinued Products 31
Oropharyngeal Candidiasis - Product Development Milestones 32
Featured News and Press Releases 32
Apr 01, 2014: BioAlliance Pharma provides an update on its partnerships for Loramyc/Oravig 32
Mar 12, 2013: Sosei Initiates Phase III Study For SO-1105 For Treatment Of Oropharyngeal Candidiasis 32
Jan 07, 2013: BioAlliance Pharma Announces Launch Of Oravig In US 33
Oct 18, 2012: BioAlliance Pharma Signs Agreement With Shafayab Gostar To Distribute Loramyc In Iran 33
Jul 02, 2012: Sosei Completes Phase I Study Of SO-1105 For Treatment Of Oropharyngeal Candidiasis 34
Mar 08, 2012: Sosei Initiates Phase I Study Of SO-1105 In Japan 34
Sep 07, 2011: BioAlliance Decides To Regain Full US Rights For Oravig 35
May 16, 2011: BioAlliance Pharma's Partner Therabel Launches Loramyc In Germany With Support Of Hikma 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 36
Disclaimer 37

List of Tables

Number of Products under Development for Oropharyngeal Candidiasis, H1 2015 7
Number of Products under Development for Oropharyngeal Candidiasis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Comparative Analysis by Unknown Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Oropharyngeal Candidiasis - Pipeline by Eisai Co., Ltd., H1 2015 16
Oropharyngeal Candidiasis - Pipeline by Onxeo SA, H1 2015 17
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Stage and Target, H1 2015 19
Number of Products by Stage and Mechanism of Action, H1 2015 20
Number of Products by Stage and Route of Administration, H1 2015 22
Number of Products by Stage and Molecule Type, H1 2015 24
Oropharyngeal Candidiasis Therapeutics - Recent Pipeline Updates, H1 2015 30
Oropharyngeal Candidiasis - Discontinued Products, H1 2015 31

List of Figures

Number of Products under Development for Oropharyngeal Candidiasis, H1 2015 7
Number of Products under Development for Oropharyngeal Candidiasis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Early Stage Products, H1 2015 12
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Top 10 Routes of Administration, H1 2015 21
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 22
Number of Products by Top 10 Molecule Types, H1 2015 23
Number of Products by Stage and Top 10 Molecule Types, H1 2015 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.